Efficacy and Safety of 0.03% Atropine Eye Drops in Controlling Myopia Progression: A One-Year Prospective Clinical Study
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Participants
2.2. Study Interventions
2.3. Study Procedures
2.4. Outcomes
2.5. Statistical Analysis
3. Results
3.1. Changes in Ophthalmic Parameters over 1-Year Follow-Up
3.2. Tolerability of 0.03% Atropine Eye Drops
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Holden, B.A.; Fricke, T.R.; Wilson, D.A.; Jong, M.; Naidoo, K.S.; Sankaridurg, P.; Wong, T.Y.; Naduvilath, T.J.; Resnikoff, S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology 2016, 123, 1036–1042. [Google Scholar] [CrossRef] [PubMed]
- Ikuno, Y. Overview of the complications of high myopia. Retina 2017, 37, 2347–2351. [Google Scholar] [CrossRef]
- Bullimore, M.A.; Ritchey, E.R.; Shah, S.; Leveziel, N.; Bourne, R.R.A.; Flitcroft, D.I. The Risks and Benefits of Myopia Control. Ophthalmology 2021, 128, 1561–1579. [Google Scholar] [CrossRef] [PubMed]
- Sankaridurg, P.; Berntsen, D.A.; Bullimore, M.A.; Cho, P.; Flitcroft, I.; Gawne, T.J.; Gifford, K.L.; Jong, M.; Kang, P.; Ostrin, L.A.; et al. IMI 2023 Digest. Investig. Ophthalmol. Vis. Sci. 2023, 64, 4–6. [Google Scholar] [CrossRef]
- Dong, J.; Zhu, Z.; Xu, H.; He, M. Myopia Control Effect of Repeated Low-Level Red-Light Therapy in Chinese Children: A Randomized, Double-Blind, Controlled Clinical Trial. Ophthalmology 2023, 130, 198–204. [Google Scholar] [CrossRef] [PubMed]
- Lawrenson, J.G.; Shah, R.; Huntjens, B.; Downie, L.E.; Virgili, G.; Dhakal, R.; Verkicharla, P.K.; Li, D.; Mavi, S.; Kernohan, A.; et al. Interventions for myopia control in children: A living systematic review and network meta-analysis. Cochrane Database Syst. Rev. 2023, 2, CD014758. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.H.; Tseng, B.Y.; Wang, J.H.; Chiu, C.J. Efficacy and Safety of Low-Dose Atropine on Myopia Prevention in Premyopic Children: Systematic Review and Meta-Analysis. J. Clin. Med. 2024, 13, 1506. [Google Scholar] [CrossRef] [PubMed]
- Huang, J.; Wen, D.; Wang, Q.; McAlinden, C.; Flitcroft, I.; Chen, H.; Saw, S.M.; Chen, H.; Bao, F.; Zhao, Y.; et al. Efficacy comparison of 16 interventions for myopia control in children: A network meta-analysis. Ophthalmology 2016, 123, 697–708. [Google Scholar] [CrossRef]
- Chia, A.; Lu, Q.S.; Tan, D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2 Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology 2016, 123, 391–399. [Google Scholar] [CrossRef]
- Yam, J.C.; Li, F.F.; Zhang, X.; Tang, S.M.; Yip, B.H.K.; Kam, K.W.; Ko, S.T.; Young, A.L.; Tham, C.C.; Chen, L.J.; et al. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology 2020, 127, 910–919. [Google Scholar] [CrossRef]
- Long, H.; Shi, M.H.; Li, X. Efficacy and safety of atropine in myopic children: A meta-analysis of randomized controlled trials. J. Fr. Ophtalmol. 2023, 46, 929–940. [Google Scholar] [CrossRef] [PubMed]
- Yam, J.C.; Zhang, X.J.; Zhang, Y.; Wang, Y.M.; Tang, S.M.; Li, F.F.; Kam, K.W.; Ko, S.T.; Yip, B.H.K.; Young, A.L.; et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology 2022, 129, 308–321. [Google Scholar] [CrossRef] [PubMed]
- Luo, Y.; Yin, Z.; Zhang, J.; Wang, W.; Huang, Y.; Li, X.; Chen, H.; Lu, F.; Bao, J. Differential Impact of 0.01% and 0.05% Atropine Eyedrops on Ocular Surface in Young Adults. Transl. Vis. Sci. Technol. 2024, 13, 22. [Google Scholar] [CrossRef] [PubMed]
- Sánchez-Tena, M.Á.; Ballesteros-Sánchez, A.; Martinez-Perez, C.; Alvarez-Peregrina, C.; De-Hita-Cantalejo, C.; Sánchez-González, M.C.; Sánchez-González, J.M. Assessing the rebound phenomenon in different myopia control treatments: A systematic review. Ophthalmic Physiol. Opt. 2024, 44, 270–279. [Google Scholar] [CrossRef] [PubMed]
- Diaz-Llopis, M.; Pinazo-Durán, M.D. Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness. Arch. Soc. Esp. Oftalmol. 2018, 93, 182–185. [Google Scholar] [CrossRef] [PubMed]
- Repka, M.X.; Weise, K.K.; Chandler, D.L.; Wu, R.; Melia, B.M.; Manny, R.E.; Kehler, L.A.F.; Jordan, C.O.; Raghuram, A.; Summers, A.I.; et al. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. JAMA Ophthalmol. 2023, 141, 756–765. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Yip, M.; Ning, Y.; Chung, J.; Toh, A.; Leow, C.; Liu, N.; Ting, D.; Schmetterer, L.; Saw, S.M.; et al. Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study. JAMA Ophthalmol. 2024, 142, 15–23. [Google Scholar] [CrossRef] [PubMed]
- Simonaviciute, D.; Grzybowski, A.; Lanca, C.; Pang, C.P.; Gelzinis, A.; Zemaitiene, R. The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions. J. Clin. Med. 2023, 12, 2314. [Google Scholar] [CrossRef] [PubMed]
- Lanca, C.; Pang, C.P.; Grzybowski, A. Effectiveness of myopia control interventions: A systematic review of 12 randomized control trials published between 2019 and 2021. Front. Public Health 2023, 11, 1125000. [Google Scholar] [CrossRef]
- Joachimsen, L.; Farassat, N.; Bleul, T.; Böhringer, D.; Lagrèze, W.A.; Reich, M. Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: A pilot study. Int. Ophthalmol. 2021, 41, 2001–2008. [Google Scholar] [CrossRef]
- Polling, J.R.; Kok, R.; Tideman, J.; Meskat, B.; Klaver, C. Effectiveness study of atropine for progressive myopia in Europeans. Eye 2016, 30, 998–1004. [Google Scholar] [CrossRef] [PubMed]
- Polling, J.R.; Tan, E.; Driessen, S.; Loudon, S.E.; Loudon, E.; Wong, H.-L.; Van Der Schans, A.; Klaver, C.C.W.; Tideman, L.; Klaver, C.C.W. A 3-year follow-up study of atropine treatment for progressive myopia in Europeans. Eye 2020, 34, 2020–2028. [Google Scholar] [CrossRef] [PubMed]
- Sze, S.; Lee, Y.; Lingham, G.; Mforsci, M.B.; Sanfilippo, P.G.; Franzco, A.K.; Franchina, M.; Chia, A.; Loughman, J.; Flitcroft, D.I.; et al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial. Clin. Exp. Ophthalmol. 2022, 50, 1001–1012. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, R.A. Statistical guidelines for the analysis of data obtained from one or both eyes. Ophthalmic Physiol. Opt. 2013, 33, 7–14. [Google Scholar] [CrossRef] [PubMed]
- Desmond, T.; Arthur, P.; Watt, K. Comparison of central corneal thickness measurements by ultrasound pachymetry and 2 new devices, Tonoref III and RS-3000. Int. Ophthalmol. 2019, 39, 917–923. [Google Scholar] [CrossRef] [PubMed]
- Simsek, M.; Oral, Y.; Erogul, O.; Sabaner, M.C.; Simsek, C.; Yorukoglu, S. Comparison of the results of four different refraction measurement devices in children with retinoscopy. Rom. J. Ophthalmol. 2022, 66, 337. [Google Scholar] [CrossRef] [PubMed]
- Morgan, I.G.; Iribarren, R.; Fotouhi, A.; Grzybowski, A. Cycloplegic refraction is the gold standard for epidemiological studies. Acta Ophthalmol. 2015, 93, 581–585. [Google Scholar] [CrossRef] [PubMed]
- Langenbucher, A.; Szentmáry, N.; Cayless, A.; Hoffmann, P.; Wendelstein, J.; Cooke, D. Repeatability of biometric measures from the IOLMaster 700 in a cataractous population. PLoS ONE 2024, 19, e0297869. [Google Scholar] [CrossRef]
- Armstrong, R.A.; Davies, L.N.; Dunne, M.C.M.; Gilmartin, B. Statistical guidelines for clinical studies of human vision. Ophthalmic Physiol. Opt. 2011, 31, 123–136. [Google Scholar] [CrossRef]
- Yam, J.C.; Zhang, X.J.; Zhang, Y.; Yip, B.H.K.; Tang, F.; Wong, E.S.; Bui, C.H.T.; Kam, K.W.; Ng, M.P.H.; Ko, S.T.; et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA 2023, 329, 472–481. [Google Scholar] [CrossRef]
- Moriche-Carretero, M.; Revilla-Amores, R.; Gutiérrez-Blanco, A.; Moreno-Morillo, F.J.; Martinez-Perez, C.; Sánchez-Tena, M.Á.; Alvarez-Peregrina, C. Five-year results of atropine 0.01% efficacy in the myopia control in a European population. Br. J. Ophthalmol. 2023, 108, 715–719. [Google Scholar] [CrossRef] [PubMed]
- Wang, M.; Cui, C.; Yu, S.A.; Liang, L.L.; Ma, J.X.; Fu, A.C. Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial. Front. Pediatr. 2023, 11, 1095495. [Google Scholar] [CrossRef] [PubMed]
- Zadnik, K.; Schulman, E.; Flitcroft, I.; Fogt, J.S.; Blumenfeld, L.C.; Fong, T.M.; Lang, E.; Hemmati, H.D.; Chandler, S.P. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol. 2023, 141, 990–999. [Google Scholar] [CrossRef] [PubMed]
- Chan, R.; Faao, M.; Cs, R.; Boptom, C.; Cho, P.; Fbcla, F. Effect of cycloplegia on axial length and anterior chamber depth measurements in children Sin Wan Cheung MPhil FAAO. Clin. Exp. Optom. 2009, 92, 476–481. [Google Scholar] [CrossRef] [PubMed]
- Qu, G.; Wang, B.; Ding, S.; Liu, X.; Gao, L.; Wang, X. Effects of Cycloplegic Agents on Ocular Parameters in Children with Myopia and Hyperopia. J. Ophthalmol. 2023, 2023, 9003942. [Google Scholar] [CrossRef] [PubMed]
- Li, F.F.; Kam, K.W.; Zhang, Y.; Tang, S.M.; Young, A.L.; Chen, L.J.; Tham, C.C.; Pang, C.P.; Yam, J.C. Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study. Ophthalmology 2020, 127, 1603–1611. [Google Scholar] [CrossRef] [PubMed]
- Gong, Q.; Janowski, M.; Luo, M.; Wei, H.; Chen, B.; Yang, G.; Liu, L. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017, 135, 624–630. [Google Scholar] [CrossRef] [PubMed]
- Kaymak, H.; Graff, B.; Schaeffel, F.; Langenbucher, A.; Seitz, B.; Schwahn, H. A retrospective analysis of the therapeutic effects of 0.01% atropine on axial length growth in children in a real-life clinical setting. Graefes Arch. Clin. Exp. Ophthalmol. 2021, 259, 3083–3092. [Google Scholar] [CrossRef] [PubMed]
- Medghalchi, A.; Behboudi, H.; Akbari, M.; Moghadam, R.S.; Kazemnejad, E.; Sabnan, S. The Preventive Role of Atropine Eye Drops on Myopia Progression: A Double-Blind Randomized Clinical Trial. Int. J. Prev. Med. 2023, 14, 45. [Google Scholar] [CrossRef]
- Agyekum, S.; Chan, P.P.; Zhang, Y.; Huo, Z.; Yip, B.H.K.; Ip, P.; Tham, C.C.; Chen, L.J.; Zhang, X.J.; Pang, C.P.; et al. Cost-effectiveness analysis of myopia management: A systematic review. Front. Public Health 2023, 11, 1093836. [Google Scholar] [CrossRef]
- Agyekum, S.; Chan, P.P.; Adjei, P.E.; Zhang, Y.; Huo, Z.; Yip, B.H.K.; Ip, P.; Wong, I.C.K.; Zhang, W.; Tham, C.C.; et al. Cost-Effectiveness Analysis of Myopia Progression Interventions in Children. JAMA Netw. Open 2023, 6, E2340986. [Google Scholar] [CrossRef] [PubMed]
Variables | Control Group (n = 41) | 0.03% Atropine Eye Drops Group (n = 31) | p-Value |
---|---|---|---|
Gender (male, n (%)) | 14 (34.1%) | 10 (32.3%) | 0.866 |
Age at the study’s commencement (years) | 10 (6–12) | 10 (6–12) | 0.789 |
Self-reported age at first diagnosis of myopia (years) | 9 (5–12) | 8 (4–12) | 0.615 |
SE (D) | −2.51 (0.91) | −2.67 (0.98) | 0.478 |
AL (mm) | 24.23 (1.13) | 24.65 (0.82) | 0.083 |
IOP (mmHg) | 17.56 (3.20) | 17.43 (2.57) | 0.885 |
CCT (μm) | 556.85 (31.95) | 548.39 (34.18) | 0.284 |
ACD (mm) | 3.86 (0.21) | 3.85 (0.19) | 0.913 |
LT (mm) | 3.30 (0.15) | 3.29 (0.12) | 0.771 |
Variables | Control Group (n = 41) | 0.03% Atropine Eye Drops Group (n = 31) | p-Value |
---|---|---|---|
SE (D) | −0.60 (0.50) | −0.34 (0.44) | 0.024 |
AL (mm) | 0.31(0.20) | 0.19 (0.17) | 0.015 |
IOP (mmHg) | 0.91 (2.13) | 0.29 (2.44) | 0.393 |
CCT (μm) | 1.18 (5.69) | 1.26 (8.28) | 0.960 |
ACD (mm) | 0.01 (0.04) | 0.03 (0.03) | 0.015 |
LT (mm) | −0.0003 (0.05) | −0.01 (0.04) | 0.290 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Simonaviciute, D.; Grzybowski, A.; Gelzinis, A.; Zemaitiene, R. Efficacy and Safety of 0.03% Atropine Eye Drops in Controlling Myopia Progression: A One-Year Prospective Clinical Study. J. Clin. Med. 2024, 13, 3218. https://doi.org/10.3390/jcm13113218
Simonaviciute D, Grzybowski A, Gelzinis A, Zemaitiene R. Efficacy and Safety of 0.03% Atropine Eye Drops in Controlling Myopia Progression: A One-Year Prospective Clinical Study. Journal of Clinical Medicine. 2024; 13(11):3218. https://doi.org/10.3390/jcm13113218
Chicago/Turabian StyleSimonaviciute, Dovile, Andrzej Grzybowski, Arvydas Gelzinis, and Reda Zemaitiene. 2024. "Efficacy and Safety of 0.03% Atropine Eye Drops in Controlling Myopia Progression: A One-Year Prospective Clinical Study" Journal of Clinical Medicine 13, no. 11: 3218. https://doi.org/10.3390/jcm13113218
APA StyleSimonaviciute, D., Grzybowski, A., Gelzinis, A., & Zemaitiene, R. (2024). Efficacy and Safety of 0.03% Atropine Eye Drops in Controlling Myopia Progression: A One-Year Prospective Clinical Study. Journal of Clinical Medicine, 13(11), 3218. https://doi.org/10.3390/jcm13113218